PharmStars reposted this
Last week, we had the privilege of welcoming the Novo Nordisk Rare Disease team to our Cambridge office. Our discussions centered on the critical importance of collaboration in driving innovation within rare disease. The visit culminated in an insightful panel discussion, moderated by our own Laura Holberger, featuring innovators from the Boston community who are driving innovation within rare disease: Patrick R Connelly, Naomi Fried, Ph.D., Aimee Raleigh, and joining virtually, Anna Greka, MD, PhD (not pictured). Rare diseases are more common than you think, and for people living with rare diseases, the unmet need remains high. This reality underscores the ongoing necessity for investment in rare disease research, where partnerships can play a pivotal role in advancing scientific progress. From our conversations, three key insights stood out to me: 1. There remains a vast opportunity to leverage precision medicine in tackling rare diseases. 2. Research in rare diseases can create a domino effect: addressing one rare disease target could unravel complexities in others and may also inform treatments for more common conditions. 3. Every contributor in the life sciences ecosystem has a vital part to play in advancing rare disease research and the power of collaborative efforts to reach our common goals. A huge thank you to our Rare Disease leadership team for joining us and to our panelists for the enriching dialogue. #LifeSciences #Biotechnology
Uli Stilz Thank you for sharing! I especially like the second point about the domino effect of rare disease research, particularly in neurodegenerative diseases. What are some of the most promising areas of cross-disease learning you're seeing right now?
It was a pleasure to join you and the rare disease leadership team for this panel, Uli! PharmStars is delighted to be focusing its current cohort on "digital innovations in rare disease." It really takes an ecosystem to address the many challenges that patients with rare disease face!
Congratulations - sounds like it was an incredible panel with important learnings to share. Thanks, Uli Stilz, for including PharmStars in the conversation!
We’re honored that our CEO, Naomi Fried, Ph.D., had the opportunity to contribute to this important dialogue. Thank you for including her in such a thoughtful and timely discussion. It’s true that collaboration is essential to advancing innovation in rare disease, which is why our current cohort is focused on digital solutions in this space. Clearly, Novo Nordisk is leading by example.